07:00 , Jul 9, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ras homolog enriched in striatum (RHES; RASD2; TEM2)

Neurology INDICATION: Huntington's disease (HD) Mouse studies suggest inhibiting RHES in the brain could help treat HD. In a transgenic mouse model of HD expressing mutant huntingtin (HTT) , systemic homozygous and heterozygous knockout of...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin complex 1 (mTORC1); RASD family member 2 (RASD2; Rhes; TEM2)

Neurology INDICATION: Huntington's disease (HD) Studies in patient samples and mice suggest increasing mTORC1 signaling could help treat HD. In striatal tissues samples from HD patients and a mouse model of HD, mTORC1 activity was...
08:00 , Jan 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) RASD family member 2 (RASD2; Rhes; TEM2); mammalian target of rapamycin (mTOR; FRAP; RAFT1) In vitro and mouse studies suggest inhibiting Rhes...
07:00 , Jun 25, 2009 |  BC Innovations  |  Cover Story

Low-Rhes approach to Huntington's

A central mystery of Huntington's disease has been why the mutant form of the huntingtin protein responsible for the condition is found throughout the body but only causes pathology in the brain's corpus striatum. Researchers...
07:00 , Jun 25, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Huntingtin (HTT; HD); Rhes (RASD2) Cell-culture studies suggest that blocking the interaction between Rhes and mutant HTT could help treat HD. HD...